148 related articles for article (PubMed ID: 7891326)
1. Alkylation of mu opioid receptors by beta-funaltrexamine in vivo: comparison of the effects on in situ binding and heroin self-administration in rats.
Martin TJ; Dworkin SI; Smith JE
J Pharmacol Exp Ther; 1995 Mar; 272(3):1135-40. PubMed ID: 7891326
[TBL] [Abstract][Full Text] [Related]
2. Effects of intracerebroventricular administration of beta-funaltrexamine on [3H]DAMGO binding to rat brain sections.
Martin TJ; Dworkin SI; Smith JE
J Pharmacol Exp Ther; 1993 Oct; 267(1):506-14. PubMed ID: 8229781
[TBL] [Abstract][Full Text] [Related]
3. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
4. Effects of intracerebroventricular administration of beta-funaltrexamine on DAMGO-stimulated [35S]GTP-gamma-S binding in rat brain sections.
Martin TJ; Sim LJ; Selley DE; deMontis MG; Childers SR
Synapse; 1997 Nov; 27(3):177-82. PubMed ID: 9329153
[TBL] [Abstract][Full Text] [Related]
5. Differential involvement of mu-opioid receptors in the rostral versus caudal nucleus accumbens in the reinforcing effects of heroin in rats: evidence from focal injections of beta-funaltrexamine.
Martin TJ; Kim SA; Lyupina Y; Smith JE
Psychopharmacology (Berl); 2002 May; 161(2):152-9. PubMed ID: 11981595
[TBL] [Abstract][Full Text] [Related]
6. Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex.
Rothman RB; Bykov V; Mahboubi A; Long JB; Jiang Q; Porreca F; de Costa BR; Jacobson AE; Rice KC; Holaday JW
Synapse; 1991 Jun; 8(2):86-99. PubMed ID: 1652797
[TBL] [Abstract][Full Text] [Related]
7. beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence.
Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW
J Pharmacol Exp Ther; 1988 Nov; 247(2):405-16. PubMed ID: 2846819
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of delta(2)-opioid receptors by naltrindole-5'-isothiocyanate attenuates heroin self-administration but not antinociception in rats.
Martin TJ; Kim SA; Cannon DG; Sizemore GM; Bian D; Porreca F; Smith JE
J Pharmacol Exp Ther; 2000 Sep; 294(3):975-82. PubMed ID: 10945849
[TBL] [Abstract][Full Text] [Related]
9. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
Tam SW; Liu-Chen LY
J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
Mjanger E; Yaksh TL
J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
[TBL] [Abstract][Full Text] [Related]
11. Effects of beta-funaltrexamine on dose-effect curves for heroin self-administration in rats: comparison with alteration of [3H]DAMGO binding to rat brain sections.
Martin TJ; DeMontis MG; Kim SA; Sizemore GM; Dworkin SI; Smith JE
Drug Alcohol Depend; 1998 Oct; 52(2):135-47. PubMed ID: 9800143
[TBL] [Abstract][Full Text] [Related]
12. Behavioral effects of opioid peptides selective for mu or delta receptors. I. Morphine-like discriminative stimulus effects.
Locke KW; Holtzman SG
J Pharmacol Exp Ther; 1986 Sep; 238(3):990-6. PubMed ID: 3018230
[TBL] [Abstract][Full Text] [Related]
13. Studies on kinetics of [3H]beta-funaltrexamine binding to mu opioid receptor.
Liu-Chen LY; Li SX; Tallarida RJ
Mol Pharmacol; 1990 Feb; 37(2):243-50. PubMed ID: 2154672
[TBL] [Abstract][Full Text] [Related]
14. [3H] beta-funaltrexamine ([3H] beta-FNA) binds irreversibly to mu opioid receptors in the rat brain: autoradiographic study.
Liu-Chen LY; Li SX; Rohrbach KW; Lewis ME
Prog Clin Biol Res; 1990; 328():61-4. PubMed ID: 2154819
[No Abstract] [Full Text] [Related]
15. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
[TBL] [Abstract][Full Text] [Related]
16. Beta-[3H]funaltrexamine-labeled mu-opioid receptors: species variations in molecular mass and glycosylation by complex-type, N-linked oligosaccharides.
Liu-Chen LY; Chen C; Phillips CA
Mol Pharmacol; 1993 Oct; 44(4):749-56. PubMed ID: 8232225
[TBL] [Abstract][Full Text] [Related]
17. Neuronal adaptations, neuroendocrine and immune correlates of heroin self-administration.
Weber RJ; Gomez-Flores R; Smith JE; Martin TJ
Brain Behav Immun; 2009 Oct; 23(7):993-1002. PubMed ID: 19467321
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
19. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice.
Burke TF; Woods JH; Lewis JW; Medzihradsky F
J Pharmacol Exp Ther; 1994 Nov; 271(2):715-21. PubMed ID: 7965787
[TBL] [Abstract][Full Text] [Related]
20. Differential regional effects of methadone maintenance compared to heroin dependence on mu-opioid receptor desensitization in rat brain.
Martin TJ; Kahn WR; Xiao R; Childers SR
Synapse; 2007 Mar; 61(3):176-84. PubMed ID: 17152089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]